- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06199531
Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency
A Phase 1/2/3 Open-label, Single Arm, Dose-finding Study to Investigate Long-term Safety, Tolerability and Efficacy of GS-100, an Adeno-associated Virus Serotype 9 (AAV9) Vector-mediated Gene Transfer of Human NGLY1, in Patients With NGLY1 Deficiency
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Regina Deck, RN/MSN/CCRP
- Phone Number: 805-857-3860
- Email: gina@gracescience.com
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- Not yet recruiting
- Oakland Children's Hospital (UCSF Benioff)
-
Principal Investigator:
- Alexander Fay, MD
-
Contact:
- Jill Dwyer, MBS, CCRP
- Phone Number: 510-428-3885
- Email: jill.nicholas@ucsf.edu
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Texas Children's Hospital (Baylor College of Medicine)
-
Principal Investigator:
- Bernhard Suter, MD
-
Contact:
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be 2 to 18 years of age, inclusive, at the time of signing the informed consent form (ICF)
- Patients with a confirmed diagnosis of NGLY1 Deficiency based on detection of biallelic pathogenic variants in the NGLY1 gene via commercially available molecular genetic sequencing
Patients with at least one of the following signs or symptoms:
- Global developmental delay and/or intellectual disability
- Hyperkinetic movement disorder
- Transient elevation of transaminases
- (Hypo)alacrima
- Peripheral neuropathy
- For patients with epilepsy who require anti-seizure medications for seizure control: must be on a stable regimen for 28 days prior to enrollment
- Patients willing and capable per investigator opinion to comply with study procedures and requirements
- Females of childbearing potential must have a negative serum pregnancy test at screening and must agree to use an acceptable method of highly effective contraception from screening through the end of the study
- Patients or parent(s)/guardian(s) must be willing and able to provide written consent after the nature of the study has been explained and prior to performance of any research-related procedures
Exclusion Criteria:
- Patients at Level 5 of both the Gross Motor Function Classification System Expanded and Revised (GMFCS E&R) and the Communication Function Classification System (CFCS) scales as assessed by the investigator
- Contraindication to use of corticosteroids or history of a condition that could worsen with corticosteroid therapy, as assessed, and determined by the investigator
Signs / symptoms of increased intracranial pressure (ICP), history of space occupying lesion, or ventricular shunt that would preclude ICV procedures or safety assessments
a. If clinical signs or symptoms of increased ICP are present (such as headache, vomiting, altered mental status), an ophthalmology examination will be performed to assess for papilledema and/or venous pulsations
- Have active malignancy (except non-melanoma skin cancer), autoimmune, metabolic (i.e., diabetes), hematologic, cardiac, or renal disease, or uncontrolled epilepsy, that is of clinical significance defined as requiring regular medical attention or treatment
Vital signs outside age-based normative values:
- Blood pressure: values > 99th percentile as cited in the National Heart, Lung and Blood Institute (NHLBI) guidelines for blood pressure levels based on subject's age, height and sex (nhlbi.nih.gov/files/docs/guidelines/child_tbl.pdf)
- Temperature: evidence of fever such as body temperature (e.g., orally measured) of 38.0°C (100.3°F)
- Respiratory rate in breaths per minute: toddler (1-3 years old): 24-40; preschooler (4-5 years old): 22-34 breaths per minute; school-aged child (6-12 years old): 18-30 breaths per minute; adolescence (13-18 years old): 12-16.
- Oxygen saturation on room air < 92%
- Any condition that in the opinion of the investigator or the study medical monitor would prevent the patient from fully complying with the requirements of the study (including the corticosteroid treatment outline in the protocol) and/or would impact or interfere with the evaluation and interpretation of patient safety or efficacy results
- Known allergy or hypersensitivity to the GS-100 investigational product formulation
- Prior treatment with gene therapy
- Treatment with any investigational product (IP) within 30 days or 5 half-lives of the IP, whichever is longer, prior to screening period. For patients who have received a prior investigational product, all ongoing AEs experienced while receiving the investigational product must have been resolved prior to screening for this study
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study that does not interfere with the requirements of the current protocol and does not have the potential to impact the evaluation of safety and efficacy of GS-100
Liver dysfunction at screening as defined by the following
- ALT: > 3 x upper limit of normal (ULN)
- aspartate aminotransferase (AST): > 3 x ULN
- INR: ≥1.4 x ULN
- Total bilirubin: > 2 x ULN unless Gilbert's syndrome is documented
- Any current infection with hepatitis B virus (HBV) as evidenced by positive HBV surface antigen (HBsAg), and/or HBV core antibody (HBcAb) at screening. Isolated HBsAb positivity for HBV vaccination in conjunction with negative confirmatory HBV DNA testing at screening is not exclusionary
- Any prior or current infection with hepatitis C virus (HCV) as evidenced by positive HCV antibody testing and confirmed by positive polymerase chain reaction (PCR) RNA testing at screening
Any of the following abnormal laboratory values:
- Hemoglobin level: < 9 g/dL
- Absolute neutrophil count: < 1000 cells/microliter
- Platelet count: < 100,000/mm3
- Creatinine: > 1.25 x ULN
- Have a major surgery planned during the screening period through 52 weeks following GS-100 infusion, including major dental procedures (e.g., wisdom tooth extraction)
- Pregnant or breastfeeding female patient
- Patients that demonstrate elevated serum adrenocorticotropic hormone (ACTH) 1.5 times the upper limit of normal for the reference range must be referred for consultation with a pediatric endocrinologist to rule out primary adrenal insufficiency prior to being enrolled into the study. Patients may re-screen for participation in the study after medical consultation and / or possible treatment has been initiated to address any adrenal insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1a
13-18 years old, then 6-12 years old (Low dose GS-100)
|
A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Other Names:
|
Experimental: Cohort 2a
13-18 years old, then 6-12 years old (Mid dose GS-100)
|
A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Other Names:
|
Experimental: Cohort 3a
13-18 years old, then 6-12 years old (High dose GS-100)
|
A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Other Names:
|
Experimental: Cohort 1b
2-5 years old (Low dose GS-100)
|
A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Other Names:
|
Experimental: Cohort 2b
2-5 years old (Mid dose GS-100)
|
A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Other Names:
|
Experimental: Cohort 3b
2-5 years old (High dose GS-100)
|
A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events (AEs) and serious AEs (SAEs)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Change in liver size by palpation
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Complete blood count (CBC)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Coagulation as measured by prothrombin time (PT)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Partial prothrombin time (aPTT)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
International normalized ratio (INR)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Gamma-glutamyl transferase (GGT)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Alkaline phosphatase (ALP)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Alanine aminotransferase (ALT)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Serum troponins
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Change in nerve conduction velocity (NCV) as assessed by nerve conduction studies
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
To assess for inflammation or evidence of microgliosis or astrocytosis on MRI
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Change in cardiac size as assessed by chamber size and wall thickness on echocardiogram
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Change in cardiac function as assessed by ejection fraction on echocardiogram
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Sodium (meq/L)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Potassium (meq/L)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Chloride (meq/L)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Bicarbonate (meq/L)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Blood urea nitrogen (BUN) (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Creatinine (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Glucose (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Total protein (g/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Albumin (g/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Total bilirubin (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Direct bilirubin (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Calcium (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Phosphate (mg/dL)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Alkaline phosphatase (U/L)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Lactic dehydrogenase (U/L)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of GNA (GlcNAc-Asn, or N-acetylglucosamine) level in CSF
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
|
Change from baseline at 52 weeks in weight (Z-score)
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline at 52 weeks in Pediatric Quality of Life Inventory (PedsQL)
Time Frame: 52 weeks
|
Total score 0-100; a higher score reflects a higher quality of life
|
52 weeks
|
Change from baseline at 52 weeks in Clinical Global Impression of Change (CGI-C)
Time Frame: 52 weeks
|
Range from 1-7, with 1 being marked improvement
|
52 weeks
|
Change from baseline at 52 weeks in Clinical Global Impression of Severity (CGI-S)
Time Frame: 52 weeks
|
Range from 1-7, with 1 being normal/no impairment
|
52 weeks
|
Change from baseline at 52 weeks in Caregiver Global Impression of Severity (CaGI-S)
Time Frame: 52 weeks
|
Range from 1-7, with 1 being normal/no impairment
|
52 weeks
|
Change from baseline at 52 weeks in peripheral nerve function measured by nerve conduction velocity (NCV) in msecs
Time Frame: 52 weeks
|
52 weeks
|
|
Assessment of NGLY1 and capsid-specific cellular immunity by enzyme-linked immunosorbent spot (ELISpot) on peripheral blood mononuclear cells (PBMC)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
|
Detection of antibodies against AAV9 capsid (AAV9 Total antibodies, AAV9 Neutralizing antibodies) and NGLY1 (NGLY1 Total antibodies)
Time Frame: 5 years (multiple visits)
|
5 years (multiple visits)
|
|
Change from baseline at 52 weeks in Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV)
Time Frame: 52 weeks
|
Standard scores are based on a mean of 100 and a standard deviation of 15; a higher score reflects a higher level of skill
|
52 weeks
|
Change from baseline at 52 weeks in Vineland Adaptive Behavior Scales-3 assessment (Vineland-3) for the Communication, Daily Living skills, Socialization, and Motor domains
Time Frame: 52 weeks
|
Standard scores for domains are based on a mean of 100 and a standard deviation of 15; a higher score reflects a higher level of skill
|
52 weeks
|
Change from baseline at 52 weeks in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
Time Frame: 52 weeks
|
Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-559; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill.
|
52 weeks
|
Change from baseline at 52 weeks in Gross Motor Function Measure (GMFM)
Time Frame: 52 weeks
|
Scores range from 0-264; a higher score reflects a higher level of skill.
|
52 weeks
|
Change from baseline at 52 weeks in seizure frequency in subjects with seizures
Time Frame: 52 weeks
|
52 weeks
|
|
Change from baseline at 52 weeks in sitting/standing assessment at 52 weeks
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Tong S, Ventola P, Frater CH, Klotz J, Phillips JM, Muppidi S, Dwight SS, Mueller WF, Beahm BJ, Wilsey M, Lee KJ. NGLY1 deficiency: a prospective natural history study. Hum Mol Genet. 2023 Sep 5;32(18):2787-2796. doi: 10.1093/hmg/ddad106.
- Stanclift CR, Dwight SS, Lee K, Eijkenboom QL, Wilsey M, Wilsey K, Kobayashi ES, Tong S, Bainbridge MN. NGLY1 deficiency: estimated incidence, clinical features, and genotypic spectrum from the NGLY1 Registry. Orphanet J Rare Dis. 2022 Dec 17;17(1):440. doi: 10.1186/s13023-022-02592-3.
- Levy RJ, Frater CH, Gallentine WB, Phillips JM, Ruzhnikov MR. Delineating the epilepsy phenotype of NGLY1 deficiency. J Inherit Metab Dis. 2022 May;45(3):571-583. doi: 10.1002/jimd.12494. Epub 2022 Mar 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-100-A301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NGLY1 Deficiency
-
Stanford UniversityGrace Science FoundationTerminated
-
Baylor College of MedicineGrace Science FoundationRecruiting
-
Eva Morava-KoziczChildren's Hospital of Philadelphia; Seattle Children's HospitalNot yet recruiting
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Washington University School of MedicineUniversity of California, Davis; Universidad San Francisco de Quito; Pan American...CompletedCholine Deficiency | Vitamin B-12 Deficiency | Lipids Deficiency | Amino Acids DeficiencyEcuador
-
Texas A&M UniversityUnknownCognitive Change | Nutritional Anemia | Diet, Healthy | Nutrient Deficiency | Diet; Deficiency | Visual Spatial Processing | Dietary Deficiency | Dietary B12 Deficiency | Dietary Zinc Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Deficiency of Selenium and Vitamin EUnited States
-
SourseCitruslabsActive, not recruitingMood | Energy Supply; Deficiency | B12 Deficiency VitaminUnited States
-
University of California, DavisUniversity of California, San Francisco; University of Rhode Island; Ethiopian... and other collaboratorsEnrolling by invitationVitamin B 12 Deficiency | Folate Deficiency | Iodine Deficiency | Anemia Deficiency | Salt Intake | Anemia MacrocyticEthiopia
-
ProofPilotJoovvUnknownTestosterone Deficiency | Estrogen DeficiencyUnited States
-
Meir Medical CenterCompletedFolic Acid Deficiency | Vitamin B12 DeficiencyIsrael
Clinical Trials on GS-100
-
Gilead SciencesActive, not recruitingChronic Hepatitis BTaiwan, New Zealand
-
Gilead SciencesCompletedHCV InfectionUnited States, Netherlands, Germany
-
Gilead SciencesCompletedNonalcoholic SteatohepatitisUnited States, France
-
Gilead SciencesCompletedGenital WartsUnited States
-
Gilead SciencesOno Pharmaceutical Co. Ltd; Galapagos NVCompletedSjogren's SyndromeUnited States, Spain, United Kingdom, Poland
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...Completed
-
Gesynta Pharma ABCTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden ABCompleted
-
Gilead SciencesCompleted